In this study we utilized bulk tissue gene expression profiling [21] and digital spatial profiling (DSP) of proteins to characterized the TME of HER2+ primary and metastatic tumors from multiple patients and tissue regions to understand changes in immune contexture as tumors evolve after metastatic migration during therapy. This evidence concerns the gene ERBB2 and metastatic neoplasm.